查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930110

全球心臟生物標記市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Cardiac Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 135 Pages | 商品交期: 請詢問到貨日

價格

心臟生物標記市場成長驅動因素

全球心臟生物標記市場在心血管疾病 (CVD) 的早期診斷和管理中發揮著至關重要的作用。心臟生物標記是內源性物質，例如酵素、荷爾蒙和蛋白質，它們在異常心臟事件期間釋放到血液中。 這些生物標記有助於醫療專業人員診斷危及生命的疾病，例如心肌梗塞、急性冠狀動脈綜合徵 (ACS) 和充血性心臟衰竭。

根據 Fortune Business Insights 的數據顯示，2025 年全球心臟生物標記市場價值為 209 億美元。預計到 2026 年，該市場將成長至 234.5 億美元，到 2034 年將達到 602.9 億美元，2026 年至 2034 年的複合年增長率 (CAGR) 為 12.53%。這一強勁的成長前景得益於心血管疾病盛行率的上升、技術的進步以及快速診斷測試的日益普及。

市場規模與關鍵指標

  • 市場規模（2025年）：209億美元
  • 市場規模（2026年）：234.5億美元
  • 市場規模（2034年）：602.9億美元
  • 複合年增長率（2026-2034年）：12.53%
  • 主要地區（2025年）：北美（市佔率：38.94%）

北美地區憑藉其先進的醫療保健基礎設施、心血管疾病高發病率以及對創新生物標記檢測技術的早期應用，在2025年佔了市場主導地位。

市場趨勢

影響心臟生物標記市場的最顯著趨勢之一是即時檢測（POC​​）生物標記檢測的日益普及。 與傳統的實驗室檢測相比，即時檢測 (POC) 可顯著縮短診斷時間。例如，羅氏的 Elexis Troponin T Gen 5 Stat 檢測可在約 9 分鐘內提供結果，從而提高急救效率。此趨勢在已開發經濟體和新興經濟體中均呈現上升趨勢。

市場驅動因素

心血管疾病盛行率的上升是市場成長的主要驅動因素。吸菸、肥胖、糖尿病和缺乏運動等生活方式因素加劇了全球心臟病負擔。此外，新冠肺炎疫情凸顯了先前患有心血管疾病患者的脆弱性。研究表明，新冠肺炎患者發生心肌損傷、心肌炎和心臟衰竭的風險更高，這顯著增加了疫情期間對心臟生物標記檢測的需求。

另一個關鍵驅動因素是新型高靈敏度生物標記檢測的推出。 西門子和雅培等公司推出的先進肌鈣蛋白檢測方法獲得監管部門批准，提高了心臟事件的早期準確檢測率，進一步推動了市場普及。

市場限制因子

儘管成長前景強勁，但挑戰包括即時檢測試劑盒供應有限以及實驗室檢測週期長。某些生物標誌物，例如 CK-MB，在症狀出現數小時後才能檢測到，這可能會延遲診斷和治療，尤其是在緊急情況下。

細分市場分析

依適應症劃分，市場可分為心肌梗塞、充血性心臟衰竭、急性冠狀動脈綜合症和其他。 受全球急性冠狀動脈綜合症發病率上升的推動，急性冠狀動脈綜合症細分市場預計將在2026年佔主導地位，市場佔有率達55.74%。

依生物標記類型劃分，肌鈣蛋白預計將佔最大的市場佔有率，達50.26%，這主要歸功於其高特異性以及在心肌梗塞和急性冠脈綜合徵診斷中的廣泛應用。其他細分市場包括肌酸激酶、腦鈉肽（BNP）和肌紅蛋白。

依終端用戶劃分，醫院預計將在2026年佔主導地位，市佔率達52.32%。這主要得益於住院患者數量的增加、發展中國家基礎設施的不斷完善以及有利的報銷政策。

區域分析

  • 北美：該市場仍是領先區域，預計到 2025 年將達到 81.4 億美元。
  • 歐洲：預計成長強勁，主要受心肌梗塞和急性冠狀動脈綜合症 (ACS) 病例增加的推動。
  • 亞太地區：由於醫療基礎設施的擴張以及中國、印度和日本等國家/地區應用率的提高，預計亞太地區將以顯著的複合年增長率增長。
  • 拉丁美洲、中東和非洲：由於認知度低和技術應用緩慢，預期成長較為溫和。

產業主要參與者

在全球心臟生物標記市場運作的主要公司包括：羅氏 (F. Hoffmann-La Roche)、雅培 (Abbott)、西門子 (Siemens)、貝克曼庫爾特 (Beckman Coulter)、Bio-Rad Laboratories、賽默飛世爾科技 (Thermo Fisher Sciificbio) 和生物梅里埃 (Mérieux)。 這些公司正專注於創新、產品發布和監管審批，以鞏固其市場地位。

市場規模單位：價值（十億美元）

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 主要地區和國家心血管疾病盛行率（2025 年）
  • COVID-19 對體外診斷市場的影響概述
  • 主要公司新產品發布
  • 主要趨勢：併購等
  • 已採取的主要措施企業和政府如何克服 COVID-19 的影響
  • 摘要：COVID-19 對心臟檢測的影響

第五章：全球心臟生物標記市場分析：洞察與預測（2021-2034）

  • 主要分析/摘要
  • 市場分析、洞察與預測：依適應症劃分
    • 心肌梗塞
    • 充血性心臟衰竭
    • 急性冠狀動脈綜合症
    • 其他
  • 市場分析、洞察與預測：依生物標記劃分
    • 肌鈣蛋白
    • 肌酸激酶-MB (CK-MB)
    • B型鈉尿肽 (BNP)
    • 肌紅蛋白
    • 其他
  • 市場分析，洞察與預測：依最終用戶劃分
    • 醫院
    • 專科診所
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美心臟生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲心臟生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區心臟生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲心臟生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東與非洲心臟生物標記市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 主要的產業趨勢
  • 世界市場佔有率分析(2021年)
  • 企業簡介
  • F. Hoffmann-La Roche AG
  • Abbott
  • Siemens AG
  • Creative Diagnostics
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Other Prominent Players

第12章 策略性建議

Product Code: FBI101233

Growth Factors of cardiac biomarkers Market

The global cardiac biomarkers market plays a critical role in the early diagnosis and management of cardiovascular diseases (CVDs). Cardiac biomarkers are endogenous substances such as enzymes, hormones, and proteins that are released into the bloodstream during abnormal cardiac events. These biomarkers assist healthcare professionals in diagnosing life-threatening conditions such as myocardial infarction, acute coronary syndrome (ACS), and congestive heart failure.

According to Fortune Business Insights, the global cardiac biomarkers market was valued at USD 20.9 billion in 2025. The market is projected to grow to USD 23.45 billion in 2026 and further reach USD 60.29 billion by 2034, registering a compound annual growth rate (CAGR) of 12.53% during 2026-2034. The strong growth outlook is supported by increasing cardiovascular disease prevalence, technological advancements, and rising adoption of rapid diagnostic tests.

Market Size and Key Metrics

  • 2025 Market Size: USD 20.9 billion
  • 2026 Market Size: USD 23.45 billion
  • 2034 Market Size: USD 60.29 billion
  • CAGR (2026-2034): 12.53%
  • Dominant Region (2025): North America (38.94% market share)

North America dominated the market in 2025 due to advanced healthcare infrastructure, a high incidence of cardiovascular diseases, and early adoption of innovative biomarker testing technologies.

Market Trends

One of the most prominent trends shaping the cardiac biomarkers market is the increasing adoption of point-of-care (POC) biomarker testing. POC tests significantly reduce diagnosis time compared to conventional laboratory-based testing. For instance, Roche's Elecsys Troponin T Gen 5 Stat test provides results in approximately nine minutes, improving emergency care efficiency. This trend is gaining traction in both developed and emerging economies.

Market Drivers

The rising prevalence of cardiovascular diseases is the primary driver of market growth. Lifestyle factors such as smoking, obesity, diabetes, and physical inactivity are contributing to the increasing burden of heart diseases globally. Additionally, the COVID-19 pandemic highlighted the vulnerability of patients with pre-existing cardiovascular conditions. Studies showed higher risks of myocardial injury, myocarditis, and heart failure among COVID-19 patients, which significantly increased demand for cardiac biomarker testing during the pandemic period.

Another key driver is the introduction of novel and high-sensitivity biomarker tests. Regulatory approvals for advanced troponin assays from companies such as Siemens and Abbott have improved early and accurate detection of cardiac events, further boosting market adoption.

Market Restraints

Despite strong growth prospects, the market faces challenges such as limited availability of point-of-care testing kits and delayed test results from laboratory-based methods. Some biomarkers, including CK-MB, require several hours post-symptom onset to be detectable, which can delay diagnosis and treatment, particularly in emergency settings.

Segmentation Analysis

By Indication, the market is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, and others. The acute coronary syndrome segment dominated with a 55.74% share in 2026, driven by the rising incidence of ACS globally.

By Biomarker Type, troponin held the largest share at 50.26% in 2026, owing to its high specificity and widespread use in diagnosing myocardial infarction and ACS. Other segments include creatine kinase, BNP, myoglobin, and others.

By End User, hospitals dominated the market with a 52.32% share in 2026, supported by increasing hospital admissions, expanding infrastructure in developing countries, and favorable reimbursement policies.

Regional Analysis

  • North America: Market size reached USD 8.14 billion in 2025 and remains the leading region.
  • Europe: Strong growth driven by increasing myocardial infarction and ACS cases.
  • Asia Pacific: Expected to grow at a significant CAGR due to expanding healthcare infrastructure and rising adoption in China, India, and Japan.
  • Latin America & Middle East & Africa: Moderate growth due to limited awareness and slower technology adoption.

Key Industry Players

Major players operating in the global cardiac biomarkers market include F. Hoffmann-La Roche AG, Abbott, Siemens AG, Beckman Coulter, Bio-Rad Laboratories, Thermo Fisher Scientific, and bioMerieux SA. These companies focus on innovation, product launches, and regulatory approvals to strengthen their market positions.

Conclusion

In conclusion, the global cardiac biomarkers market is poised for robust growth from 2025 to 2034, driven by the increasing prevalence of cardiovascular diseases, technological advancements, and rising demand for rapid diagnostic solutions. With the market expected to grow from USD 20.9 billion in 2025 to USD 60.29 billion by 2034, cardiac biomarkers will remain a cornerstone of modern cardiovascular diagnostics. Continued innovation, improved accessibility of point-of-care testing, and expanding healthcare infrastructure-particularly in emerging economies-will play a crucial role in shaping the future of this market.

Unit Value (USD billion)

Segmentation By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By Biomarker

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • B-type Natriuretic Peptide (BNP)
  • Myoglobin
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • The Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Cardiovascular Disorders, By Key Regions/ Key Countries, 2025
  • 4.2. Overview of Impact of COVID-19 on the In-vitro Diagnostics Market
  • 4.3. New Product Launches, By Key Market Players
  • 4.4. Key Industry Developments such as Mergers and Acquisitions
  • 4.5. Key Steps Taken by Companies, Government, etc. to Navigate the Impact of Covid-19
  • 4.6. Overview: Impact of Covid-19 on Cardiac Tests

5. Global Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Myocardial Infarction
    • 5.2.2. Congestive Heart Failure
    • 5.2.3. Acute Coronary Syndrome
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 5.3.1. Troponin
    • 5.3.2. Creatine kinase-MB (CK-MB)
    • 5.3.3. B-type natriuretic peptide (BNP)
    • 5.3.4. Myoglobin
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Speciality Clinics
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Myocardial Infarction
    • 6.2.2. Congestive Heart Failure
    • 6.2.3. Acute Coronary Syndrome
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 6.3.1. Troponin
    • 6.3.2. Creatine kinase-MB (CK-MB)
    • 6.3.3. B-type natriuretic peptide (BNP)
    • 6.3.4. Myoglobin
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Speciality Clinics
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Myocardial Infarction
    • 7.2.2. Congestive Heart Failure
    • 7.2.3. Acute Coronary Syndrome
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 7.3.1. Troponin
    • 7.3.2. Creatine kinase-MB (CK-MB)
    • 7.3.3. B-type natriuretic peptide (BNP)
    • 7.3.4. Myoglobin
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Speciality Clinics
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Myocardial Infarction
    • 8.2.2. Congestive Heart Failure
    • 8.2.3. Acute Coronary Syndrome
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 8.3.1. Troponin
    • 8.3.2. Creatine kinase-MB (CK-MB)
    • 8.3.3. B-type natriuretic peptide (BNP)
    • 8.3.4. Myoglobin
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Speciality Clinics
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Myocardial Infarction
    • 9.2.2. Congestive Heart Failure
    • 9.2.3. Acute Coronary Syndrome
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 9.3.1. Troponin
    • 9.3.2. Creatine kinase-MB (CK-MB)
    • 9.3.3. B-type natriuretic peptide (BNP)
    • 9.3.4. Myoglobin
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Speciality Clinics
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Myocardial Infarction
    • 10.2.2. Congestive Heart Failure
    • 10.2.3. Acute Coronary Syndrome
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Biomarkers
    • 10.3.1. Troponin
    • 10.3.2. Creatine kinase-MB (CK-MB)
    • 10.3.3. B-type natriuretic peptide (BNP)
    • 10.3.4. Myoglobin
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals
    • 10.4.2. Speciality Clinics
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2021)
  • 11.3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, and Financials (based on availability))
    • 11.3.1. F. Hoffmann-La Roche AG
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT,
      • 11.3.1.4. Recent Developments,
      • 11.3.1.5. Strategies,
      • 11.3.1.6. Financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT,
      • 11.3.2.4. Recent Developments,
      • 11.3.2.5. Strategies,
      • 11.3.2.6. Financials (based on availability)
    • 11.3.3. Siemens AG
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT,
      • 11.3.3.4. Recent Developments,
      • 11.3.3.5. Strategies,
      • 11.3.3.6. Financials (based on availability)
    • 11.3.4. Creative Diagnostics
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT,
      • 11.3.4.4. Recent Developments,
      • 11.3.4.5. Strategies,
      • 11.3.4.6. Financials (based on availability)
    • 11.3.5. Beckman Coulter, Inc.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT,
      • 11.3.5.4. Recent Developments,
      • 11.3.5.5. Strategies,
      • 11.3.5.6. Financials (based on availability)
    • 11.3.6. Bio-Rad Laboratories, Inc.
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT,
      • 11.3.6.4. Recent Developments,
      • 11.3.6.5. Strategies,
      • 11.3.6.6. Financials (based on availability)
    • 11.3.7. Thermo Fisher Scientific Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT,
      • 11.3.7.4. Recent Developments,
      • 11.3.7.5. Strategies,
      • 11.3.7.6. Financials (based on availability)
    • 11.3.8. bioMerieux SA
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products,
      • 11.3.8.3. SWOT,
      • 11.3.8.4. Recent Developments,
      • 11.3.8.5. Strategies,
      • 11.3.8.6. Financials (based on availability)
    • 11.3.9. Other Prominent Players
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products,
      • 11.3.9.3. SWOT,
      • 11.3.9.4. Recent Developments,
      • 11.3.9.5. Strategies,
      • 11.3.9.6. Financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 2: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 3: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 4: Global Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Region, 2021-2034
  • Table 5: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 6: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 7: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 8: North America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country, 2021-2034
  • Table 9: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 10: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 11: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 12: Europe Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 14: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 15: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 18: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 19: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 20: Latin America Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Indication, 2021-2034
  • Table 22: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by Biomarker, 2021-2034
  • Table 23: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Cardiac Biomarkers Market Revenue (USD Bn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiac Biomarkers Market Revenue Breakdown (USD Bn, %) by Region, 2025& 2034
  • Figure 2: Global Cardiac Biomarkers Market Value Share (%), by Indication, 2025& 2034
  • Figure 3: Global Cardiac Biomarkers Market Forecast (USD Bn), by Myocardial Infarction, 2021-2034
  • Figure 4: Global Cardiac Biomarkers Market Forecast (USD Bn), by Congestive Heart Failure, 2021-2034
  • Figure 5: Global Cardiac Biomarkers Market Forecast (USD Bn), by Acute Coronary Syndrome, 2021-2034
  • Figure 6: Global Cardiac Biomarkers Market Forecast (USD Bn), by Others, 2021-2034
  • Figure 7: Global Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025& 2034
  • Figure 8: Global Cardiac Biomarkers Market Forecast (USD Bn), by Troponin, 2021-2034
  • Figure 9: Global Cardiac Biomarkers Market Forecast (USD Bn), by Creatine kinase-MB (CK-MB), 2021-2034
  • Figure 10: Global Cardiac Biomarkers Market Forecast (USD Bn), by B-type natriuretic peptide (BNP), 2021-2034
  • Figure 11: Global Cardiac Biomarkers Market Forecast (USD Bn), by Myoglobin, 2021-2034
  • Figure 12: Global Cardiac Biomarkers Market Forecast (USD Bn), by Others, 2021-2034
  • Figure 13: Global Cardiac Biomarkers Market Value Share (%), by End User, 2025& 2034
  • Figure 14: Global Cardiac Biomarkers Market Forecast (USD Bn), by Hospitals, 2021-2034
  • Figure 15: Global Cardiac Biomarkers Market Forecast (USD Bn), by Speciality Clinics, 2021-2034
  • Figure 16: Global Cardiac Biomarkers Market Value (USD Bn), by Region, 2025& 2034
  • Figure 17: North America Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 18: North America Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 19: North America Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 20: North America Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 21: North America Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 22: North America Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 23: North America Cardiac Biomarkers Market Value (USD Bn), By Country, 2025& 2034
  • Figure 24: North America Cardiac Biomarkers Market Value Share (%), By Country, 2025
  • Figure 25: Europe Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 26: Europe Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 27: Europe Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 28: Europe Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 29: Europe Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 30: Europe Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 31: Europe Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 32: Europe Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 33: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 34: Asia Pacific Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 35: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 36: Asia Pacific Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 37: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 38: Asia Pacific Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 39: Asia Pacific Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 40: Asia Pacific Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 41: Latin America Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 42: Latin America Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 44: Latin America Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 45: Latin America Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 46: Latin America Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 47: Latin America Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 48: Latin America Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 49: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by Indication, 2025& 2034
  • Figure 50: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 51: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by Biomarker, 2025& 2034
  • Figure 52: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by Biomarker, 2025
  • Figure 53: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), by End User, 2025& 2034
  • Figure 54: Middle East & Africa Cardiac Biomarkers Market Value Share (%), by End User, 2025
  • Figure 55: Middle East & Africa Cardiac Biomarkers Market Value (USD Bn), By Country/ Sub-region, 2025& 2034
  • Figure 56: Middle East & Africa Cardiac Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cardiac Biomarkers Market Share (%), By Company, 2025